Talk:Ellipta

This is the talk page for discussing improvements to the Ellipta article.
This is not a forum for general discussion of the article's subject.

Put new text under old text. Click here to start a new topic.
New to Wikipedia? Welcome! Learn to edit; get help.

Article policies

Find medical sources: Source guidelines · PubMed · Cochrane · DOAJ · Gale · OpenMD · ScienceDirect · Springer · Trip · Wiley · TWL

Pharmacology Mid‑importance

	This article is within the scope of WikiProject Pharmacology, a collaborative effort to improve the coverage of Pharmacology on Wikipedia. If you would like to participate, please visit the project page, where you can join the discussion and see a list of open tasks.PharmacologyWikipedia:WikiProject PharmacologyTemplate:WikiProject Pharmacologypharmacology articles
Mid	This article has been rated as Mid-importance on the project's importance scale.

Medicine Mid‑importance

	Medicine portal This article is within the scope of WikiProject Medicine, which recommends that medicine-related articles follow the Manual of Style for medicine-related articles and that biomedical information in any article use high-quality medical sources. Please visit the project page for details or ask questions at Wikipedia talk:WikiProject Medicine.MedicineWikipedia:WikiProject MedicineTemplate:WikiProject Medicinemedicine articles
Mid	This article has been rated as Mid-importance on the project's importance scale.

Ideal sources for Wikipedia's health content are defined in the guideline Wikipedia:Identifying reliable sources (medicine) and are typically review articles. Here are links to possibly useful sources of information about Ellipta.

PubMed provides review articles from the past five years (limit to free review articles)
The TRIP database provides clinical publications about evidence-based medicine.
Other potential sources include: Centre for Reviews and Dissemination and CDC

Trelegy Ellipta

According to:

"Trelegy Ellipta approved as the first once-daily single inhaler triple therapy for the treatment of appropriate patients with COPD in the US" (Press release). GlaxoSmithKline. 18 September 2017.

Trelegy Ellipta = fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI).

A news item related to a study on this agent: "GlaxoSmithKline: IMPACT Study Shows Benefits Of Trelegy Ellipta In COPD Patients". AFX News. 19 April 2018. Retrieved 2018-04-20.

--User:Ceyockey (talk to me) 01:58, 21 April 2018 (UTC)[reply]

Anoro

How can you get it without insurance and a reasonable price 74.69.156.226 (talk) 14:29, 27 October 2023 (UTC)[reply]